ArticleJournal for immunotherapy of cancer2026

Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Rα.

Heydar Moravej et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.